Last reviewed · How we verify

Onabotulinumtoxin A (BoNT)

Edgar LeClaire, MD · FDA-approved active Small molecule

Onabotulinumtoxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Onabotulinumtoxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia (spasmodic torticollis), Blepharospasm, Strabismus.

At a glance

Generic nameOnabotulinumtoxin A (BoNT)
Also known asBotox, Allergan
SponsorEdgar LeClaire, MD
Drug classNeurotoxin; botulinum toxin serotype A
TargetSNAP-25 (synaptosome-associated protein of 25 kDa)
ModalitySmall molecule
Therapeutic areaNeurology; Dermatology; Aesthetics
PhaseFDA-approved

Mechanism of action

The toxin is a zinc-dependent endopeptidase that cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neurotransmitter signaling at the neuromuscular junction, resulting in flaccid paralysis of injected muscles. The effect is temporary, lasting 3–4 months, after which nerve terminals regenerate and function is restored.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: